Phase 3 Readout
ENTA: Phase 3 Topline: A Randomized, Open, Multicenter Phase III Clinical Trial of Combination of Sintilimab Injection (IBI
December 30, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 30, 2026
- Company
- ENANTA PHARMACEUTICALS INC (ENTA)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized, Open, Multicenter Phase III Clinical Trial of Combination of Sintilimab Injection (IBI
- Indication
- Colorectal Cancer Stage IV